Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - HC Wainwright issued their FY2029 earnings estimates for shares of Monopar Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee expects that the company will earn $3.66 per share for the year. HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share.
Other equities analysts have also recently issued reports about the company. Rodman & Renshaw started coverage on Monopar Therapeutics in a research note on Friday, October 11th. They set a "buy" rating and a $50.00 price objective on the stock. Piper Sandler began coverage on shares of Monopar Therapeutics in a report on Friday, January 10th. They set an "overweight" rating and a $72.00 target price on the stock.
Read Our Latest Report on MNPR
Monopar Therapeutics Stock Up 5.4 %
NASDAQ:MNPR traded up $2.14 during trading hours on Thursday, reaching $41.46. 122,014 shares of the stock were exchanged, compared to its average volume of 58,667. Monopar Therapeutics has a 52 week low of $1.54 and a 52 week high of $41.94. The stock has a market capitalization of $252.91 million, a P/E ratio of -21.05 and a beta of 1.23. The firm has a 50 day simple moving average of $24.19 and a 200-day simple moving average of $12.34.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09.
Insider Buying and Selling
In other news, CFO Karthik Radhakrishnan acquired 1,550 shares of the company's stock in a transaction that occurred on Monday, October 28th. The shares were acquired at an average price of $16.25 per share, with a total value of $25,187.50. Following the acquisition, the chief financial officer now directly owns 1,550 shares in the company, valued at approximately $25,187.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 34.90% of the company's stock.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Recommended Stories
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
